Literature DB >> 15265907

Alpha-fetoprotein impairs APC function and induces their apoptosis.

Soon Ho Um1, Catherine Mulhall, Akeel Alisa, Annette Robyn Ives, John Karani, Roger Williams, Antonio Bertoletti, Shahriar Behboudi.   

Abstract

alpha-Fetoprotein (AFP) is a tumor-associated Ag, and its serum level is elevated in patients with hepatocellular carcinoma (HCC). In vitro, AFP induces functional impairment of dendritic cells (DCs). This was demonstrated by the down-regulation of CD40 and CD86 molecules and the impairment of allostimulatory function. Also, AFP was found to induce significant apoptosis of DCs, and AFP-treated DCs produced low levels of IL-12 and TNF-alpha, a cytokine pattern that could hamper an efficient antitumor immune response. Ex vivo, APCs of patients with HCC and high levels of AFP produced lower levels of TNF-alpha than that of healthy individuals. In conclusion, these results illustrate that AFP induces dysfunction and apoptosis of APCs, thereby offering a mechanism by which HCC escapes immunological control.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265907     DOI: 10.4049/jimmunol.173.3.1772

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Relationship between the changes of VEGF level and dendritic cells in peripheral blood of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  Jinwen Liu; Jilin Yi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-02

2.  Adenoendocrine cell carcinoma of the gallbladder producing a high level of alpha-fetoprotein.

Authors:  Hideki Fujii; Kanji Yamaguchi; Naoki Ohnishi; Masafumi Sakamoto; Tohru Ohkawara; Yoshihiko Sawa; Koichi Nishida; Yasuo Ohkawara; Yoshinori Harada; Hideo Tanaka; Tetsuro Takamatsu; Yoshito Itoh
Journal:  Clin J Gastroenterol       Date:  2012-06-07

3.  Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population.

Authors:  Subramaniam Mohana Devi; Vellingiri Balachandar; Meyyazhagan Arun; Shanmugam Suresh Kumar; Balasubramanian Balamurali Krishnan; Keshavarao Sasikala
Journal:  Dig Dis Sci       Date:  2012-10-02       Impact factor: 3.199

4.  Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma.

Authors:  Shahriar Behboudi; Stephen P Pereira
Journal:  World J Hepatol       Date:  2010-07-27

5.  Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells.

Authors:  Angela D Pardee; Jian Shi; Lisa H Butterfield
Journal:  J Immunol       Date:  2014-10-29       Impact factor: 5.422

6.  α-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells.

Authors:  M Yamamoto; T Tatsumi; T Miyagi; H Tsunematsu; H Aketa; A Hosui; T Kanto; N Hiramatsu; N Hayashi; T Takehara
Journal:  Clin Exp Immunol       Date:  2011-05-19       Impact factor: 4.330

7.  AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.

Authors:  Viktoria N Evdokimova; Yang Liu; Douglas M Potter; Lisa H Butterfield
Journal:  J Immunother       Date:  2007 May-Jun       Impact factor: 4.456

8.  Chromatin-bound p53 anchors activated Smads and the mSin3A corepressor to confer transforming-growth-factor-beta-mediated transcription repression.

Authors:  Deepti Srinivas Wilkinson; Wen-Wei Tsai; Maria A Schumacher; Michelle Craig Barton
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

9.  Down-regulation of beta-centractin might be involved in dendritic cells dysfunction and subsequent hepatocellular carcinoma immune escape: a proteomic study.

Authors:  Yong-Qiang Weng; Shuang-Jian Qiu; Yin-Kun Liu; Jia Fan; Qiang Gao; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-07       Impact factor: 4.553

10.  Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.

Authors:  S Behboudi; A Alisa; S Boswell; J Anastassiou; A A Pathan; R Williams
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.